AI Article Synopsis
- The study evaluates the safety and effectiveness of Transarterial radioembolization (TARE) for patients with liver-dominant metastatic renal cell carcinoma (RCC), revealing promising outcomes.
- A total of 36 patients underwent TARE treatments, resulting in a median overall survival of 19.3 months and a high objective response rate of 89%.
- The findings suggest that TARE is a viable option for improving survival in RCC patients with liver metastases, and certain factors like treatment response and liver function can indicate better survival rates.
Article Abstract
Purpose: The management of Renal cell carcinoma (RCC) patients with liver metastases is challenging. Liver-directed therapy, such as Transarterial radioembolization (TARE), is a reasonable option for these patients; however, its safety and efficacy are not well characterized. This study evaluated the safety and efficacy of TARE in patients with liver-dominant metastatic RCC.
Materials And Methods: This is a retrospective, single-center study. Thirty-eight patients' medical records were reviewed who underwent TARE between January 1, 2009, and December 31, 2019, in a tertiary cancer center. Two were excluded from further analysis. Thirty-six patients received 51 TARE treatments. Median follow-up time was 18.2 months. Imaging data were evaluated using mRECIST or RECIST 1.1 criteria. Toxicities, treatment responses, liver progression-free survival (LPFS), and median overall survival (OS) were calculated. Univariate and multivariate analyses were conducted to reveal predictors of OS.
Results: Median OS from TARE was 19.3 months (95% CI, 22.6-47.4) and from diagnosis of liver metastases was 36.5 months (95% CI: 26.4-49.8). Mild, grade 1 or 2, biochemical toxicity developed in 27 patients (75%). Grade 3-4 toxicity was noted in two patients (5.5%). The objective response rate was 89%; the disease control rate was 94% (21 complete response, 11 partial response, two stable disease, and two progressive disease). Univariate and multivariate analyses showed longer survival in patients who had objective response, lower lung shunt fraction, and better baseline liver function.
Conclusions: TARE is safe and effective and led to promising overall survival in patients with liver-dominant metastatic RCC.
Level Of Evidence: Level 3, retrospective cohort study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00270-021-02925-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lesion Volume Divided by ADC Measures Is an Independent Prognostic Marker in Colorectal Liver Metastasis Treated by Y90-radioembolization.
In Vivo
December 2024
Department of Radiology and Nuclear Medicine, University Hospital Magdeburg, University of Magdeburg, Magdeburg, Germany.
Background/aim: To assess the ability of apparent diffusion coefficient (ADC) at baseline in predicting overall survival in patients who undergo Y90-radioembolization (Y90-RE) for liver-dominant metastatic colorectal cancer (mCRC) in the salvage situation.
Patients And Methods: A retrospective review of 411 lesions in 63 patients with refractory mCRC treated with Y90-RE was conducted. Manual region of interest (ROI) measurements were applied using a whole lesion and volume method.
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases.
Cochrane Database Syst Rev
August 2024
Chair of Epidemiology and Preventive Medicine, Department of Hygiene and Dietetics, Jagiellonian University Medical College, Krakow, Poland.
Background: The liver is affected by two groups of malignant tumours: primary liver cancers and liver metastases. Liver metastases are significantly more common than primary liver cancer, and five-year survival after radical surgical treatment of liver metastases ranges from 28% to 50%, depending on primary cancer site. However, R0 resection (resection for cure) is not feasible in most people; therefore, other treatments have to be considered in the case of non-resectability.
View Article and Find Full Text PDFOutcomes Analysis of Yttrium-90 Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the Radiation-Emitting SIR-Spheres in Nonresectable (RESiN) Registry.
J Vasc Interv Radiol
November 2024
Division of Interventional Radiology, Stanford University Medical Center, Stanford, California. Electronic address:
Purpose: To characterize the response and survival outcomes of yttrium-90 (Y) transarterial radioembolization (TARE) for unresectable, liver-dominant metastases from primary neoplasms other than colorectal carcinoma.
Materials And Methods: This study included 1,474 patients enrolled in the Radiation-Emitting Society of Interventional Radiology (SIR)-Spheres in Nonresectable Liver Tumor registry who received resin Y-TARE as part of their oncologic management for unresectable primary or secondary liver tumors (NCT02685631). Of these patients, 33% (481/1,474) were treated for liver metastases of noncolorectal origin (m-non-CRC) compared with 34% (497/1,474) treated for metastatic colorectal cancer (mCRC) and 34% (496/1,474) treated for hepatocellular carcinoma.
Intra-arterial PRRT with Lu-177 DOTATATE in Liver-dominant Metastatic Neuroendocrine Tumors: Early Assessment of Efficacy and Toxicity.
Indian J Nucl Med
May 2024
Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Purpose: We proposed to administer Lu-177-DOTATATE in intra-arterial (IA) mode for higher first-pass localization to somatostatin receptors, higher residence time in liver metastases, and more radiation to tumor. This study aimed at assessing early hematological, renal and hepatotoxicity; and objective response to IA peptide receptor radionuclide therapy (PRRT).
Materials And Methods: Fourteen patients (4 females and 10 males) were prospectively assessed.
The Current State of Systemic Therapy of Metastatic Uveal Melanoma.
Am J Clin Dermatol
September 2024
Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), CCC Erlangen-EMN, 91054, Erlangen, Germany.
Uveal melanoma (UM) is genetically a distinct tumor compared to cutaneous melanoma (CM), and due to its low mutational burden, it is far less perceptible to the immune system. Thus, treatments that have revolutionized the treatment of CM remain widely inefficient in metastatic UM or only demonstrate effectiveness in a small subpopulation of patients. To this end, the therapeutic benefit of immune checkpoint blockade is very limited and may come at the expense of severe immune-related adverse events that could potentially affect all organ systems.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!